Minimal inhibitory concentrations of clindamycin, minocycline, metronidazole, penicillin, and carbenicillin were determined by agar dilution against 150 recent clinical isolates of anaerobic bacteria. Ninety-nine percent of Bacteroides fragilis and all B. melaninogenicus, Clostridium perfringens, and Fusobacterium were inhibited by clindamycin at 3.1 Ag/ml. Only 58% of other clostridial species were inhibited by this concentration of clindamycin. Minocycline at 3.1 ,ug/ml inhibited 72%3 of C. perfringens, 81% of other Clostridium species, and 66, 75, and 100% of B. fragilis, B. melaninogenicus, and Fusobacterium, respectively. Metronidazole at 12.5 ug/ml inhibited all bacteria tested. B. fragilis was resistant to both penicillin and carbenicillin at 6.2 sg/ml. Concentrations of 25 ,g/ml for penicillin and 100 ,ug/ml for carbenicillin were needed to inhibit more than 90% of B. fragilis. Organisms other than B. fragilis were moderately or extremely susceptible to the penicillins.
Because of the relatively long in vitro generation times and the fastidious nature of anaerobic bacteria, rapid determination of antimicrobial susceptibilities is not feasible. Therefore, it is necessary to monitor the specific susceptibility patterns of recent clinical isolates for possible changes in resistance, particularly to widely used drugs. A survey of the in vitro antimicrobial susceptibilities of anaerobic bacteria isolated during 1971 was reported from this laboratory by Martin et al. (17) .
For the present in vitro study, clindamycin was chosen because it has been recommended by several investigators as one of the drugs of choice for treatment of anaerobic infections (2, 3, 7, 10, 11, 16, 27) . Minocycline was included because it is a derivative of tetracycline, the former drug of choice against Bacteroides fragilis infection (13) . Recent encouraging reports on the effectiveness of metronidazole against anaerobes (19, 26, 29) prompted us to investigate the activity of this antiparasitic drug. Penicillin and carbenicillin were evaluated to determine the possibility of using high doses of penicillin or its derivatives as components of the initial antimicrobial therapy of infections when the cause is unknown but may include anaerobic bacteria. Gas-liquid chromatographic analysis of fermentation acids and the interpretation of these data were as described in the Anaerobic Laboratory Manual of the Virginia Polytechnic Institute (12) . To keep isolated strains until susceptibility testing was performed, equal volumes of a thioglycolate broth (enriched with rabbit serum) culture and whole defibrinated sheep blood were mixed, flash-frozen in an alcohol-Dry Ice bath, and stored at -60 C. All anaerobic incubation in this study was in the GasPak system (BBL) at 37 C.
Antimicrobial susceptibility testing was performed by the agar dilution method essentially as described by Sutter and Washington (25) . The antimicrobial agents, in appropriate dilutions in sterile distilled water, were incorporated into a brain heart infusion agar base with added 5% whole defibrinated sheep blood and vitamin K1 (menadione, 0.5 Ag/ml). The concentration of metronidazole was calculated on a dry weight basis; the remaining drugs were diluted on the basis of the activity specified by the manufacturer. Minocycline at a concentration of 3.1 gg/ml inhibited 66 and 75% of strains of B. fragilis and B. melaninogenicus, respectively (Table 3) . Within the genus Clostridium, 72% of the strains of C. perfringens and 81% of the other species were susceptible to 0.4 ,ug/ml or less. All seven strains of Fusobacterium tested were inhibited by minocycline at 0.2 ,g/ml.
At a concentration of 12.5 ,ug/ml, metronidazole inhibited all strains used in this study (Table 4) . At 6.2 ,g/ml, penicillin was effective against 96 and 87% of the strains of C. perfringens and other clostridial species, respectively, as well as against all Fusobacterium strains tested (Table  5) . However, only 7% of strains of B. fragilis were inhibited by this concentration. Penicillin was more effective against B. melaninogenicus and the two other Bacteroides species tested here (B. pneumosintes and B. clostridiiformis). Carbenicillin at 100 ,ug/ml inhibited 99% of the strains of B. fragilis (Table 6 ). The other Bacteroidaceae were inhibited by 12.5 ,g/ml and in most instances by considerably lower concentrations. All strains of C. perfringens were inhibited by 12.5 ,ug/ml and 96% were inhibited by 0.8 ug/ml. Other species of Clostridium were less susceptible to carbenicillin. C. aminovalericum Clostridium dp. (17, 21, 30) . There seems to be general agreement that clindamycin is active against C. perfringens, but the question of its activity against other clostridial species merits further study.
An increasing resistance of B. fragilis to tetracycline has been described by several authors (5, 15, 17-19, 23, 32) . A derivative of it, minocycline, was found to be approximately twice as active against B. fragilis in this study as was tetracycline in the study by Martin et al. (17) . Against the other organisms in this study, the activity of minocycline was comparable to that of tetracycline in the former study. If one accepts the recommendation of the National Committee for Clinical Laboratory Standards Subcommittee on Antimicrobial Susceptibility Testing (1) that an MIC of 6.2 sg/ml be considered indicative of intermediate susceptibility for the tetracyclines, then 80 to 89% of the strains of Bacteroides and Clostridium tested here would be so classified with respect to minocycline. The present data on the activity of minocycline against C. perfringens differ from those of Sapico et al. (21) who found that 100% of the C. perfringens strains tested were inhibited at 0.2 usg/ml. This concentration inhibited 72% of the strains tested here with the remaining 28% requiring at least 6.2 ,ug/ml for inhibition.
Metronidazole, the drug of choice for trichomoniasis and amoebiasis (9, 20) , has recently been shown to be effective against anaerobic bacteria in vitro and in limited clinical trials (26) . Whelan and Hale (29) and Nastro and Finegold (19) demonstrated that, in addition to being bacteriostatic, metronidazole is also bactericidial in vitro against anaerobic bacteria. The MIC values of metronidazole in this study were higher than those reported but still are within easily achievable serum levels. According to Davies (6) , a dosage of 1 g four times a day will provide serum levels of 15 to 75.5 tsg/ml. Whelan and Hale (29) state that a single 2-g dose will provide a serum level of 46 ,ug/ml. All anaerobes tested here were inhibited by metronidazole at 12.5 ug/ml or less. At present, administration of this agent is limited to the oral route. The apparent bactericidal activity of this drug against anaerobic bacteria should encourage further clinical trials.
Our results with penicillin are similar to those of other workers (5, 14, 18, 21, 24, 32) , including the earlier study from this laboratory (18) , except that, as with clindamycin, clostridia other than C. perfringens required significantly higher concentrations for inhibition than they did 3 years ago. In general, the organisms in this group that showed in vitro resistance to clindamycin were susceptible to both penicillin and minocycline. Keusch and O'Connell (15) (2, 4, 5, 10, 16, 17, 27) , seems to make unnecessary high-dose penicillin therapy for coverage of Bacteroides in sepsis of unknown cause.
Nearly all of the strains tested were inhibited by carbenicillin at 100 ,ug/ml, a concentration considered to be indicative of susceptibility of Pseudomonas aeruginosa (1) . This antibiotic is frequently used in the initial therapy for sepsis of unknown cause, because of its activity against P. aeruginosa and some species of Enterobacteriaceae, and it would be useful to know whether or not its activity against anaerobes in vivo is like that demonstrated in vitro.
Clindamycin was highly effective against the majority of anaerobic isolates tested with the exception of Clostridium species other than C. perfringens. Because B. fragilis is the predominant anaerobe involved in clinically significant anaerobic bacteremia (31), clindamycin and chloramphenicol (not tested in this study) remain the drugs of choice for serious anaerobic infections. Minocycline was more effective than tetracycline against B. fragilis, but it failed to inhibit one-third of this group of organisms at expected peak serum levels of 3.1 gg/ml. After further clinical trials and the development of a parenteral form of the drug, metronidazole may ANTIMICROB. AG. CHEMOTHER. 
